Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/ro-antibody - Associated cardiac manifestations of neonatal lupus

Circulation

Volumn 126, Issue 1, 2012, Pages 76-82

  Izmirly, Peter M ^a   Costedoat Chalumeau, Nathalie ^b   Pisoni, Cecilia N ^c   Khamashta, Munther A ^d   Kim, Mimi Y ^e   Saxena, Amit ^a   Friedman, Deborah ^f   Llanos, Carolina ^g   Piette, Jean Charles ^b   Buyon, Jill P ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SORBONNE UNIVERSITÉ   (France)

^c CEMIC   (Argentina)

^d ST THOMAS HOSPITAL   (United Kingdom)

^e ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^f NEW YORK MEDICAL COLLEGE   (United States)

^g PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

Anti SSA Ro antibody; Cardiomyopathies; Congenital heart block; Hydroxychloroquine; Neonatal lupus; Prevention and control

Indexed keywords

HYDROXYCHLOROQUINE; RO ANTIBODY;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DATA BASE; ETHNICITY; FEMALE; FETUS; HEART DISEASE; HUMAN; MAJOR CLINICAL STUDY; MATERNAL WELFARE; NEONATAL LUPUS; PREGNANCY; PRIORITY JOURNAL; PROPENSITY SCORE; RECURRENCE RISK; RISK REDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; ANTIBODIES, ANTINUCLEAR; COHORT STUDIES; DATABASES, FACTUAL; FEMALE; FRANCE; GREAT BRITAIN; HUMANS; HYDROXYCHLOROQUINE; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; RECURRENCE; RISK FACTORS; UNITED STATES;

EID: 84863625124     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.111.089268     Document Type: Article

References (36)

1. Izmirly PM, Saxena A, Kim MY, Wang D, Sahl SK, Llanos C, Friedman D, Buyon JP. Maternal and fetal factors associated with mortality and morbidity in a multi-racial/ethnic registry of anti-SSA/Ro associated cardiac neonatal lupus. Circulation. 2011;124:1927-1935.
2. Brucato A, Frassi M, Franceschini F, Cimaz R, Faden D, Pisoni MP, Muscarà M, Vignati G, Stramba-Badiale M, Catelli L, Lojacono A, Cavazzana I, Ghirardello A, Vescovi F, Gambari PF, Doria A, Meroni PL, Tincani A. Risk of congenital complete heart block in newborns of mothers with anti-Ro/SSA antibodies detected by counterimmunoelectrophoresis: a prospective study of 100 Women. Arthritis Rheum. 2001;44: 1832-1835. (Pubitemid 32758230)
3. Cimaz R, Spence DL, Hornberger L, Silverman ED. Incidence and spectrum of neonatal lupus erythematosus: a prospective study of infants born to mothers with anti-Ro autoantibodies. J Pediatr. 2003;142: 678-683. (Pubitemid 36737172)
4. Costedoat-Chalumeau N, Amoura Z, Lupoglazoff JM, Huong DL, Denjoy I, Vauthier D, Sebbouh D, Fain O, Georgin-Lavialle S, Ghillani P, Musset L, Wechsler B, Duhaut P, Piette JC. Outcome of pregnancies in patients with anti-SSA/Ro antibodies: a study of 165 pregnancies, with special focus on electrocardiographic variations in the children and comparison with a control group. Arthritis Rheum. 2004;50:3187-3194. (Pubitemid 39371995)
5. Buyon JP, Hiebert R, Copel J, Craft J, Friedman D, Katholi M, Lee LA, Provost TT, Reichlin M, Rider L, Rupel A, Saleeb S, Weston WL, Skovron ML. Autoimmune-associated congenital heart block: mortality, morbidity, and recurrence rates obtained from a national neonatal lupus registry. J Am Coll Cardiol. 1998;31:1658-1666. (Pubitemid 28273312)
6. Julkunen H, Eronen M. The rate of recurrence of isolated congenital heart block: a population based study. Arthritis Rheum. 2001;44:487-488.
7. Gladman G, Silverman ED, Yuk-Law, Luy L, Boutin C, Laskin C, Smallhorn JF. Fetal echocardiographic screening of pregnancies of mothers with anti-Ro and/or anti-La antibodies. Am J Perinatol. 2002; 19:73-80.
8. Llanos C, Izmirly PM, Katholi M, Clancy RM, Friedman DM, Kim MY, Buyon JP. Recurrence rates of cardiac manifestations associated with neonatal lupus and maternal/fetal risk factors. Arthritis Rheum. 2009;60: 3091-3097.
9. Friedman DM, Llanos C, Izmirly PM, Brock B, Byron J, Copel J, Cummiskey K, Dooley MA, Foley J, Graves C, Hendershott C, Kates R, Komissarova EV, Miller M, Paré E, Phoon CKL, Prosen T, Reisner D, Ruderman E, Samuels P, Yu JK, Kim MY, Buyon JP. Evaluation of fetuses in the Preventive IVIG Therapy for Congenital Heart Block (PITCH) study. Arthritis Rheum. 2010;62:1138-1146.
10. Pisoni CN, Brucato A, Ruffatti A, Espinosa G, Cervera R, Belmonte-Serrano M, Sánchez-Román J, García-Hernández FG, Tincani A, Bertero MT, Doria A, Hughes GR, Khamashta MA. Failure of intravenous immunoglobulin to prevent congenital heart block: findings of a multicenter, prospective, observational study. Arthritis Rheum. 2010;62:1147-1152.
11. Ambrosi A, Salomonsson S, Eliasson H, Zeffer E, Skog A, Dzikaite V, Bergman G, Fernlund E, Tingström J, Theander E, Rydberg A, Skogh T, Ohman A, Lundström U, Mellander M, Winqvist O, Fored M, Ekbom A, Alfredsson L, Källberg H, Olsson T, Gadler F, Jonzon A, Kockum I, Sonesson SE, Wahren-Herlenius M. Development of heart block in children of SSA/SSB-autoantibody-positive women is associated with maternal age and displays a season-of-birth pattern. Ann Rheum Dis. 2012;71:334-340.
12. Izmirly PM, Llanos C, Lee LA, Askanase A, Kim MY, Buyon JP. Cutaneous manifestations of neonatal lupus and risk of subsequent congenital heart block. Arthritis Rheum. 2010;62:1153-1157.
13. Eliasson H, Sonesson SE, Sharland G, Granath F, Simpson JM, Carvalho JS, Jicinska H, Tomek V, Dangel J, Zielinsky P, Respondek-Liberska M, Freund MW, Mellander M, Bartrons J, Gardiner HM; Fetal Working Group of the European Association of Pediatric Cardiology. Isolated atrioventricular block in the fetus: a retrospective, multinational, multicenter study of 175 patients. Circulation. 2011;124:1919-1926.
14. Pike JI, Donofrio MT, Berul CI. Ineffective therapy, underpowered studies, or merely too little, too late? Risk factors and impact of maternal corticosteroid treatment on outcome in antibody-associated fetal heart block. Circulation. 2011;124:1905-1907.
15. Friedman DM, Kim MY, Copel JA, Llanos C, Davis C, Buyon JP. Prospective evaluation of fetuses with autoimmune-associated congenital heart block followed in the PR Interval and Dexamethasone Evaluation (PRIDE) Study. Am J Cardiol. 2009;103:1102-1106.
16. Clancy RM, Alvarez D, Komissarova E, Barrat FJ, Swartz J, Buyon JP. Ro60-associated single-stranded RNA links inflammation with fetal cardiac fibrosis via ligation of TLRs: a novel pathway to autoimmuneassociated heart block. J Immunol. 2010;184:2148-2155.
17. Alvarez D, Briassouli P, Clancy RM, Zavadil J, Reed JH, Abellar RG, Halushka M, Fox-Talbot K, Barrat FJ, Buyon JP. A novel role of endothelin-1 in linking Toll-like receptor 7-mediated inflammation to fibrosis in congenital heart block. J Biol Chem. 2011;286:3044-3054.
18. Lafyatis R, York R, Marshak-Rothstein A. Antimalarial agents: closing the gate on toll-like receptors? Arthritis Rheum. 2006;54:3068-3070 (Pubitemid 44622073)
19. Izmirly PM, Kim MY, Llanos C, Le PU, Guerra MM, Askanase AD, Salmon JE, Buyon JP. Evaluation of the risk of anti-SSA/Ro-SSB/La antibody associated cardiac manifestations of neonatal lupus in fetuses of SLE mothers exposed to hydroxychloroquine. Ann Rheum Dis. 2010;69: 1827-1830.
20. Jaeggi ET, Silverman ED, Laskin C, Kingdom J, Golding F, Weber R. Prolongation of the atrioventricular conduction in fetuses exposed to maternal anti-Ro/SSA and anti-La/SSB antibodies did not predict progressive heart block: a prospective observational study on the effects of maternal antibodies on 165 fetuses. J Am Coll Cardiol. 2011;57: 1487-1492.
21. Brookhart M, Schneeweiss S, Rothman K, Glynn R, Avorn J, Sturmer T. Variable selection for propensity score models. Am J Epidemiol. 2006; 163:1149-1156. (Pubitemid 43987579)
22. Rubin DB, Thomas N. Matching using estimated propensity scores: relating theory to practice. Biometrics. 1996;52:249-264. (Pubitemid 26125107)
23. Matz GJ, Naunton RF. Ototoxicity of chloroquine. Arch Otolaryngol. 1969;88:370-372.
24. Paufique L, Magnard P. Retinal degeneration in 2 children following preventative antimalarial treatment of the mother during pregnancy. Bull Soc Ophthalmol Fr. 1969;69:466-467.
25. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis. 2010;69:20-28.
26. Costedoat-Chalumeau N, Amoura Z, Huong DL, Lechat P, Piette JC. Safety of hydroxychloroquine in pregnant patients with connective tissue disease: review of the literature. Autoimmun Rev. 2005;4:111-115. (Pubitemid 40255619)
27. Vroom F, de Walle HEK, van de Laar MA, Brouwers JR, de Jong-van den Berg LT. Disease-modifying antirheumatic drugs in pregnancy: current status and implications for the future. Drug Safety. 2006;29: 845-863. (Pubitemid 44511586)
28. Levy RA, Vilela VS, Cataldo MJ, Ramos RC, Duarte JL, Tura BR, Albuquerque EM, Jesús NR. Hydroxychloroquine in lupus pregnancy: a double-blind placebo controlled study. Lupus. 2001;10:401-404. (Pubitemid 32578614)
29. Clowse ME, Magder L, Witter F, Petri M. Hydroxychloroquine in lupus pregnancy. Arthritis Rheum. 2006;54:3640-3647. (Pubitemid 44737176)
30. Cortés-Hernández J, Ordi-Ros J, Paredes F, Casellas M, Castillo F, Vilardell-Tarres M. Clinical predictors of fetal and maternal outcome in systemic lupus erythematosus: a prospective study of 103 pregnancies. Rheumatology. 2002;41:643-650. (Pubitemid 34618882)
31. Alarcón GS, McGwin G, Bertoli AM, Fessler BJ, Calvo-Alén J, Bastian HM, Vilá LM, Reveille JD. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis. 2007;66: 1168-1172. (Pubitemid 47309732)
32. Pons-Estel GJ, Alarcón GS, McGwin G Jr, Danila MI, Zhang J, Bastian HM, Reveille JD, Vilá LM; Lumina Study Group. Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort. Arthritis Rheum. 2009;61: 830-839.
33. Shinohara K, Miyagawa S, Fujita T, Aono T, Kidoguchi K. Neonatal lupus erythematosus: results of maternal corticosteroid therapy. Obstet Gynecol. 1999;93:952-957. (Pubitemid 29247102)
34. Marciniak B, Patro-Maysza J, Poniedziaek-Czajkowska E, Kimber-Trojnar Z, Leszczyńska-Gorzelak B, Oleszczuk J. Glucocorticoids in pregnancy. Curr Pharm Biotechnol. 2011;12:750-757.
35. Costedoat-Chalumeau N, Amoura D, Le Thi Hong D, Wechsler B, Vauthier D, Ghillani P, Papo T, Fain O, Musset L, Piette JC. Questions about dexamethasone use for the prevention of anti-SSA related congenital heart block. Ann Rheum Dis. 2003;62:1010-1012. (Pubitemid 37159504)
36. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10:1-10. (Pubitemid 19099520)